School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

KAMADA LTD KMDA

Healthcare · Drug Manufacturers - Specialty & Generic

$7.84last close 2026-10-12 · market cap $452.45M · delayed data

Trailing returns

1M-1.01%
3M+12.39%
6M-5.74%
1Y+21.25%
5Y+61.85%

Basis: Adjusted daily closes.

What it does

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for…

Open KMDA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies